Microneedle Patch for Peanut Allergies Begins Clinical Trials | RT

Moonlight Therapeutics' microneedle patch for peanut allergy desensitisation has entered phase 1 clinical trials at Children's Healthcare of Atlanta, delivering controlled peanut protein doses through the skin in three minutes. The device, cleared by the FDA in late 2025, is designed for home use and targets a market of 1.2m+ allergic children in the US. If you're building allergen delivery or immunotherapy, you now have a proven efficacy route and a patient population that rejected the only two FDA-approved alternatives. The real market opens when this exits phase 1 - watch who acquires Moonlight or licenses this technology; that's your exit price.